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Abstract: Breast cancer has been treated successfully with selective estrogen receptor antagonists (SERMs) such as tamoxifen, receptordepleting agents such as fulvestrant, and aromatase inhibitors such as anastrozole. Selective progesterone receptor modulators (SPRMs
or PRMs) have not been studied as much and are currently under investigation for inhibition of mammary carcinogenesis in animal
models and breast cancer prevention trials in women. They might follow tamoxifen and aromatase inhibitors in the adjuvant treatment
of breast cancers with acquired resistance. These uses have not provoked ground-breaking progress or studies and PRMs do not have a
high profile. Most in vitro and in vivo studies indicate that PRMs preferentially suppress cell proliferation and also induce apoptosis. In
this review we summarized the data on the effects of PRMs and particularly of the antiprogestins RU-486 (mifepristone) and CDB-4124
(Progenta, Proellex or telapristone acetate) on breast cancer models. Both agents have been employed in preclinical and clinical studies
for prevention and treatment of breast cancer. This author believes that PRMs should be investigated more intensely.
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1. The case for progesterone receptor modulators
(PRMs) for breast cancer
PRMs have shown benefit in women with uterine
leiomyomas and endometriosis and those successes
in clinical trials have led to the realization that the
antiproliferative and pro-apoptotic actions seen may find
use in other progesterone-sensitive tissues. As a prime
developer of a lead PRM, we (Repros Therapeutics)
soon realized that those young women who used a
PRM for treatment of fibroids or endometriosis would
face an extended treatment period of months, if not
years. Those women needed assurance that the use of
these hormonal agents was not going to increase their
risk for breast cancer, particularly so in an era when
seemingly innocuous treatments such as hormone
replacement therapy (HRT) with progestins have been
shown to increase the risks of breast cancer (Rossouw
et al., 2002; Chlebowski et al., 2003; Rohan, et al.,
2008). Any possibility that risks could be mitigated and
thus prevention realized would be most welcome, to say
the least, for women taking a new PRM. Indeed, this
‘new world’ of treatments would present a new way of
looking at the problem. This paradigm requires giving
up a purely estrogen-based or estrocentic view of breast
cancer in favor of one that introduces other hormones as

drivers. Progesterone appears to be one of those drivers
but peptide growth factors including EGF and IGF1 need to be considered alongside steroids (Dressing
and Lange, 2009). We have always known that steroid
hormone-responsive therapies have not been enough and
the current evaluation of new disease usually requires the
evaluation of Her2/neu status, nodal involvement, tumor
stage and grade, some assessment of proliferation such as
Ki67, and other markers with many patients opting for an
analysis of tumor markers such as Oncotype DX. Luminal
A is the term we now use to distinguish those tumors with
the best chance for antihormone treatments, although
the presence of Her2/neu (Luminal B) adds an additional
layer of treatment for tumors that appear to be hormoneresponsive. The coming age of individualized medicine for
breast cancer would seem to require the use of multiple
markers.
We are accustomed to the linkage of breast cancer with
estrogen and its treatment with agents that oppose estrogen.
This has been a tremendous medical advance for those
women whose breast cancers present as estrogen receptor
positive (ER+) status at biopsy and surgery. It is known
that progesterone receptor presence (PR+) is estrogenregulated and its function in normal and tumor cells
requires estrogen and ER signaling (Chabbert-Buffet et al.,
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2005). As a result of endocrine therapy with tamoxifen, ER
and PR expression may decrease in breast cancer cells, but
complete receptors loss does not occur, suggesting their
potential reactivation and the development of strategies
for their further down-regulation (Bardon et al., 1987).
The SERMs predominantly affect the ERα isoform,
leading to inhibition of cell cycle progression and eventually
to cell death (Michna et al., 1989). Given the success of
SERMS, the analogous and parallel progesterone signal
through PRMs, antiprogesterone therapy would seem to
hold promise even though lagging behind in development.
Importantly, 10 years ago data from the Woman’s Health
Initiative (WHI) trial revealed a significant role for
progesterone in breast cancer development and growth.
Healthy postmenopausal women treated with the
combination of estrogen (E) and progestin (P) were 24%
more likely to develop invasive breast cancer and had
larger tumors at diagnosis (Chlebowski et al., 2003). Most
notably this effect was not seen in hysterectomized women
treated with estrogen. Indeed a nonsignificant reduction
in breast cancer incidence was observed with estrogen
alone (Rohan et al., 2008), suggesting a specific tumorpromoting effect of combination E+P therapy. Notably the
antiprogesterone RU486 (mifepristone) has been found to
reduce proliferation in normal breast tissue (ChabbertBuffet et al., 2005), and preclinical data support the concept
of mammary tumor prevention with antiprogesterone
therapy (Bardon et al., 1987; Michna et al., 1989). As a
whole these data support research into antiprogesterone
therapy for breast cancer therapy and prevention.
2. The introduction of PRMs
The relative lack of PRMs may be one reason that clinical
progress has been relatively slow. The initial antiprogestin
was RU-486 (mifepristone), which was synthesized in the
early 1980s by Roussel-Uclaf and described by Philibert
in meetings abstracts in 1981 (Philibert et al., 1981)
and 1982 (Philibert et al., 1982) and in a monograph in
1984 (Philibert, 1984). In comparison, the synthesis of
tamoxifen was in 1964 and its properties were described
by 1966 (Harper and Walpole, 1966). The extensive
antiglucocorticoid action of RU 486 was recognized early.
Nevertheless, clinical uses were quickly shown by Baulieu’s
group (Herman et al., 1982). An initial indication was
pregnancy termination and that use was constrained by
ethical and political opposition that soon found its way
into the mainstream media (Baulieu, 1994). This did
much to delay research and development. An early worker
characterized this as ‘political chemistry’ (Hodgen, 1991).
The search for new compounds was joined by the
labs of C.E. Cook at Research Triangle Park and by the
European firms Schering AG and Onganon. Noteworthy
early compounds were RTI 3121-012 (CDB-2914), ZK 98

299, and ORG 31167, among others. The caution displayed
by major American pharmaceutical companies in the
1990s over both the chemistry and the issue of pregnancy
termination seemed to delay further invention on their
part and we at Repros Therapeutics (then Zonagen, Inc.),
as a small company, were able to move into the space later
with less competition. Another complication was that
the first compounds were also antiglucocorticoids and
substantial work was done in synthesizing these mixed
steroids and finding those with activity on one receptor or
the other, i.e. dissociated binding and biological activity.
By 1994, there were many potential PRMs. This entire
story may be best appreciated through a supplement issue
to Human Reproduction and a monograph (Beier and
Spitz, 1994) published in 1994 based on a symposium held
at Mohonk Mountain, New York, in the summer of 1992.
It was recognized early that antiglucocorticoid
activity was unwanted in a potential drug to be used for
antiprogestational effects. As pointed out early by Horwitz
(Horwitz, 1993), lower antiglucocorticoid activity can
enhance the usefulness of any drug by allowing higher
dosage. Thus, the early best candidates were judged against
both activities. As an example, it has been shown that RU
486 was nearly a 10-fold better binder to the glucocorticoid
receptor (hGR) than to the hPR and a 3–4-fold better binder
to the hGR than dexamethasone (Kloosterboer et al., 1994).
In contrast, he found that ZK 98 299 (onapristone or ZK
299) bound the hGR less avidly but with an approximately
5-fold selectivity for hGR over hPR. Nevertheless, both
compounds went into clinical trials. In the case of ZK 299,
phase II trials were terminated early due to liver toxicity
found by liver function tests (Robertson et al., 1999). We at
Repros Therapeutics have also found liver toxicity at high
doses as well but believe that an optimal dosing regimen in
terms of oral dose concentration as well as an appropriate
schedule is required.
A spin-off of the Schering AG work on PRMs was the
compound Asoprisnil, which was developed through TAP
(Chen et al., 2006). Although its development appeared
to be intended for fibroids and endometriosis, problems
with uterine bleeding and endometrial changes interfered
with its further development in a 2005 phase III study.
It is unknown if there is to be further development for
oncologic indications.
Another PRM compound developed early was CDB2914 (Xu et al., 2005). A 2012 report in the New England
Journal of Medicine (Donnez et al., 2012) highlighted
a European study that showed efficacy in women with
fibroids. This drug is approved for emergency contraception
although it is not certain if it may be developed for breast
cancer.
The compound CDB-4124 was synthesized at the
Southwest Foundation for Biomedical Research under a
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contract from the Contraceptive Research Branch, Center
for Population Research, NICHD, and studied initially
under a contract to Bioquals, Inc. Its chemical similarity
to RU 486 is through its nor-19 steroidal backbone and
11b substitution. It differs at the C-21 position (Figure 1).
Another compound from this first set was CDB-4059. These
compounds and others were patented as composition-ofmatter. In 1999, Repros Therapeutics acquired rights to at
least 44 compounds that were 21-substituted. One of these
became the lead compound, CDB-4124. We determined
early that a mono-demethylated metabolite, CDB-4453,
was always found along with the parent in animal and
human serum. The metabolite was found to be active
relative to the parent. Neither compound demonstrated
significant antiglucocorticoid activity but showed high
activity as an antiprogestin. The comparisons of these 2
compounds and RU 486 have been shown by Attardi et al.
(2002, 2004).
3. PRMs in breast cancer trials
Early progesterone antagonists showed greater antitumor
activity than tamoxifen or high-dose progesterone agonists
and synergized with antiestrogens (Klijn et al., 2000).
Clinical data are meager but at least 5 studies have used
antiprogestins in women with breast cancer. One small
clinical trial in women with metastatic breast cancer has
shown that RU 486 has some efficacy against the disease
(Mandelonde, 1987). Two other studies employed RU
486 (Romieu et al., 1987; Klijn et al., 1989) as a secondline adjuvant therapy. These first 3 trials demonstrated a
complete or partial response of 12% and stable disease in 46%
of 33 patients. Two more phase II trials used mifepristone
(Perrault et al., 1996) or onapristone (Robertson et al.,
1999) as first-line therapy. Perrault et al. (1996) reported
values for partial response and stable disease similar to the

3 mentioned above. Interestingly, Robertson et al. reported
a partial response in 56% of patients and stable disease in
11% but symptoms of adrenal insufficiency (Robertson
et al., 1999). This was perhaps not totally unexpected; a
rise in serum cortisol was seen when RU 486 was used to
treat patients with meningiomas (Grunberg, 1994) and
trials of onapristone in women have been closed down
due to liver toxicity. Indeed, potential antiglucocorticoid
effects counterindicate the long-term use of RU 486. In a
study of women treated with RU 486 for endometriosis
(Kettel et al., 1991), patients were anovulatory as
expected (Liu et al., 1987) but serum estrogen levels
remained consistent with midfollicular phase and there
was evidence for hypercortisolemia and ACTH excess.
Although RU 486 can serve as the paradigm for this class
of antiprogestins, outcomes must be measured against
possible antiglucocorticoid effects (Bertagna et al., 1984). In
a study of 11 postmenopausal women with advanced breast
cancer RU-486 induced a short-term clinical response in 1
patient and stable disease in 6 others (Bakker et al., 1990).
The side effects of RU-486 in this study were mostly related
to antiglucocorticoid properties of the drug and increased
serum estradiol levels. Previous studies suggested that high
dose RU-486 can elevate serum estradiol and progesterone
levels, impacting endometrial cell proliferation (Kettel et al.,
1991).
CDB-4124 and its metabolites appear to show
less antiglucocorticoid activity compared to RU-486,
suggesting an advantage in future clinical studies (Attardi
et al., 2002, 2004). Despite the beneficial effects seen
in women with uterine fibroids (Wiehle et al., 2008)
and endometriosis (Spitz, 2009; Spitz et al., 2009), rare,
idiosyncratic liver reactions at high doses (unpublished
data) suggest that lower doses will be required for clinical
studies.
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Figure 1. Structures of RU 486 and CDB-4124.
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4. PRMs in in vivo experimental models
Classical
experiments
have
shown
DMBA
(dimethylbenz(a)-anthracene)-induced breast tumors
are inhibited by ovariectomy and maintained by estrogen
and progesterone (Huggins et al., 1962; Welsch, 1985).
Progestins increase the incidence of spontaneous
mammary tumors in dogs (Frank et al., 1979) and mice
(Nagasawa et al., 1988). We found that progesterone can
promote DMBA-induced mammary carcinogenesis in
rats (Wiehle et al., 2007). Using progestin receptor knockout (PRKO) mice, PR has been shown to be specifically
important for DMBA-induced mammary carcinogenesis
(Bakker et al., 1989). When RU-486 was used in DMBAtreated rats and in mice that spontaneously developed
ER+ mammary tumors, a significant reduction in tumor
incidence, multiplicity, and size was observed (Michna et
al., 1989; Chatterton et al., 2002). In a separate study on the
effects of RU-486 on DMBA-induced mammary tumors
in rats, a reduction in tumor multiplicity was found
in 90% of animals versus 75% of animals treated with
tamoxifen (Bakker et al., 1989). The combination of both
agents further increased their antitumor potential. The
antiprogestins Org 31710 and Org 31806 (Kloosterboer
et al., 1994) appear to be more potent than RU 486. In
the case of ZK 299, its full agonism may contribute to its
potency. The combination of tamoxifen and RU 486 is a
potent suppresser of tumor growth analogous to chemical
castration or ovariectomy (Bakker et al., 1987). The SERM
164,384 enhances the ability of onapristone to reduce
tumors in the MXT mouse mammary tumor model
(Nishino et al., 1994).
Interestingly, Dr Eva Lee of the University of California,
Irvine, conducted studies demonstrating that progesterone
provides growth signals for breast tumors in mouse
models of spontaneously developing tumors carrying
Brca-1 mutations (Poole et al., 2006). BRCA1, the protein
product of the breast cancer susceptibility gene, is known
to interact directly with ER and PR and modulates both
ligand-dependent and ligand-independent transcriptional
activities of ERa and PR. Mice in which both alleles of Brca1 and p53 have been knocked out in the mammary tissue
exhibited abnormal proliferation of mammary epithelial
cells with increased branching and alveolar formation, and
100% develop breast tumors in a median of 6.6 months.
Poole et al. (2006) found the PR levels were markedly
elevated in the mutant breast cells due to failure of the
E3 ligase activity of BRCA1 and subsequent proteosomal
degradation of PR. Treatment of mice with mifepristone
for 5 weeks completely blocked tumor formation. These
groundbreaking animal studies, epidemiologic data, and
observations of the clinical behavior of ER+ positive breast
cancers including the observation that aromatase inhibitors
have heterogeneous effects on circulating progestins

argue for the investigation of combined estrogen and
progesterone signaling blockade. Translational clinical
studies to test the central hypothesis that combined ER
and PR signaling blockade is safe and clinically effective in
treating breast cancer have not been performed. A recent
study has shown that the BRCA1 protein inhibits the
binding of PR to certain progesterone response elements
without an effect of the binding of ligand to PR (Katiyar
et al., 2009).
Our results in the DMBA tumor model (Wiehle et
al., 2007) agree with these trends and extend these data:
PRMs CDB-4124 and CDB-4059 as well as RU-486 shrunk
established tumors and prevented the appearance of new
tumors within the 28 day window of treatment (Table 1).
Rats were given DMBA at 50 days of age. Animals were
weighed and palpated for any sign of lesions or swellings.
Possible tumors were measured in 2 dimensions. If suspect
tumors grew to a size of 10 mm, the individual animal was
randomized into 1 of 15 groups. We treated the animals
for 28 days. Rats treated with vehicle alone had the original
tumor used to activate their treatment regimen and an
average of 1.67 more tumors, a total of 2.67 tumors per
rat. The addition of progesterone increased the average
number of tumors per rat to almost 5. CDB-4124 reduced
tumor number. Since each animal was enrolled into
treatment randomly based on finding 1 tumor of a given
size, we conclude that treatment with antiprogestins at
3 of the 4 top dose levels reduced the number of tumors
by suppressing the formation of new tumors during the
28-day treatment period. The tumor-inducing effects of
progesterone overwhelmed the tumor suppressing effects
of CDB-4124 if the dose of progesterone exceeded the dose
of CDB-4124 by a factor of 5 or more. We measured tumors
weekly during the trial. The data were corrected to exclude
the nonmalignant tumor types. Tumors that increased in
cross-sectional area by at least 33% were considered to be
growing. Those that decreased by approximately 33% were
considered to be regressing. Others were considered stable.
Progesterone treatment resulted in aggressively growing
tumors. The proportion of tumors regressing in the group
given progesterone (8%) is statistically the same as that of
the controls but the proportion of tumors growing was 10fold higher (80%). On the other hand, RU 486 treatment
led to no real difference in the proportion of tumors
growing or regressing. CDB-4124 at 10 mg/kg body weight
reduced the proportion of growing tumors but appeared
to exert its prime effects by increasing the proportions of
regressing tumors. At high doses, CDB-4124 might have
some agonist activity with respect to growth, albeit not
approaching that of progesterone.
We inferred that all 3 PRMS (RU 486, CDB-4124, and
CDB-4059) belong to the same class of agents. However,
at equal dose levels, CDB-4124 and CDB-4059 were more
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Table 1. Effect of selective progesterone receptor modulators on tumors.
Animals
Group

TX

with tumors in group %

Tumors

TB/animal

N
1

No TX

Tumor weight

Effects on weight

mean

median*

MWW test*

g

G

Compared to controls

12 /

13

92

32

4.7

1.91

0.80

0/

10

0

0

0

0

0

13 /

14

93

27

2.47

1.19

0.16

P = 0.012

10 /

10

100

49

7.34

1.5

0.5

P = 0.42

13 /

13

100

20

4.71

3.4

0.125

P = 0.066

10 /

11

91

18

0.48

0.26

0.075

P = 0.0003

11 /

12

92

17

4.61

2.98

0.09

P = 0.012

9/

11

82

16

0.94

0.53

0.17

P = 0.0009

12 /

12

100

29

5.1

2.26

0.77

P = 0.99

8/

10

90

18

0.92

0.46

0.18

P = 0.005

10 /

12

83

14

3.82

2.73

0.185

P = 0.013

10 /

11

91

34

5.8

1.96

0.45

P = 0.19

14 /

15

93

45

4.28

1.19

0.49

P = 0.27

11 /

11

100

41

6.16

1.65

0.49

P = 0.66

9/

11

82

12

1.24

0.93

0.17

P = 0.10

vehicle
2

No DMBA
vehicle

3

RU486
10

4

P4
10

5

4124
20

6

4124
10

7

4124
2

8

4124
1

9

4124
0.1

10

4124/P4
20/10

11

4124/P4
10/10

12

4124/P4
2/10

13

4124/P4
1/10

14

4124/P4
0.1/10

15

4059
10

effective than RU 486 in provoking tumor regression.
The order of tumor-suppressing activity by these criteria
was CDB-4059 ~ CDB-4124 > RU 486. When CDB-4124
is given alone at moderate concentrations or in excess
of progesterone, its effects predominate on growth and
regression. When progesterone is given alone or in excess
over CDB-4124 its effects are strongly growth-enhancing.
The effects of CDB-4124 are consistent with decreasing the
size of DMBA-induced mammary tumors in the rat. CDB-
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4059 may be as effective. These effects are mimicked by
effects on proliferation and apoptosis (see section below).
Christov et al. used a rat MNU model to show
predicative value in breast cancer prevention/therapy for
compounds that are both antiproliferative and proapoptotic
(e.g. SERMs and AIs) and as compared to castration and
an aromatase inhibitor (Christov et al., 2007). Tamoxifen
had proven itself useful in this model (Christov et al.,
2003). We treated nascent mammary tumors with CDB-
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4124 in this breast tumor model of prevention (Wiehle et
al., 2011). In our case, female Sprague Dawley rats at 50
days of age were intravenously injected with N-methylN-nitrosourea (MNU). Randomly selected animals were
placed into 2 arms of the study (20 rats per arm) and
received CDB-4124 at a high (30 mg) or low (3 mg) dose
in the form of a subcutaneous pellet beginning 5 days after
MNU. A third arm received a placebo pellet. The treatment
was for 90 days. The occurrence of mammary tumors was
monitored by palpation, starting 4 weeks after carcinogen
administration. Paraffin tissue sections of tumors were
stained for identification of tumor morphology as well as
with antibodies for assessment of ER, PR, and proliferationand apoptosis-related biomarkers. Blood samples were
taken for the determination of estrogen and progesterone.
As shown in Table 2 and Figure 2, treatment with CDB4124 resulted in dose-dependent reduction in mammary
gland tumor size and multiplicity. CDB-4124 prevented the
appearance and reduced the size of tumors in the 90-day
period following carcinogen insult. The higher dose level
of CDB-4124 was more effective. CDB-4124 treatment
had no effect on the serum estrogen level in the animals
compared to controls but the highest dose of CDB-4124
significantly reduced circulating progesterone by 45%.
Thus, the effects were not due to estrogen suppression.
In the course of drug development, Repros
Therapeutics conducted a 2-year carcinogenesis study
(MPI1155-006). The mammary gland of animals treated
for 2 years (the mean lifetime) with CDB-4124 showed
fewer tumors and abnormalities than controls. However,
placebo-treated animals developed spontaneously
hyperplastic and premalignant mammary lesions, as
well as cystic formations (Wiehle et al., 2011). This was
essentially the opposite of the aim of this carcinogenicity
study, which was to disclose overt tumor development
across the animal organs and lifetime. We reviewed
slides for mammary gland histology, proliferation (Ki-67
staining), and apoptosis markers from these tissues. Based
on these data, CDB-4124, when given for 2 years to female
Sprague Dawley rats, remodeled mammary morphology
by: 1) decreasing lobular differentiation of mammary
epithelial cells, as shown by a prevalence of single lobules;
2) stimulating cystic formations in the mammary gland;

and 3) suppressing lobular proliferation. These results in
the mammary gland are reminiscent of those seen in the
mammary gland of PRKO mice (Bakker et al., 1989). CDB4124 also decreased proliferative activity of mammary
epithelial cells (Table 3), but did not significantly affect
apoptosis.
5. Evidence for the cellular mode of action: uterine
proliferation and apoptosis
Under investigation is whether progesterone antagonist
may induce apoptosis by affecting pro- or antiapoptotic
proteins. This topic has been covered with respect to CDB4124 in a recent review (Christov and Wiehle, 2012) and
will be mentioned below for breast tissue. At the same
time, we believe much may be gained by looking at the
effects of PRMs on other progesterone-sensitive tissues
such as those in the female reproductive tract.
Asoprisnil, a PRM with mixed progesterone agonist/
antagonist activities, was able to reduce uterine leiomyoma
volume in a dose-dependent manner in the presence of
follicular phase estrogen (Chen et al., 2006). Studies in vitro
on cultured human uterine leiomyoma cells and matched
normal myometria showed that asoprisnil decreased
the PCNA-positive rate and PCNA protein expression
in cultured leiomyoma cells. Asoprisnil increased the
TUNEL-positive rate, cleaved caspase-3, and cleaved
poly (adenosine 5’-diphosphate-ribose) polymerase
expression and decreased Bcl-2 protein expression in
cultured leiomyoma cells. These effects were dose- and
time-dependent. However, in cultured myometrial cells,
asoprisnil did not affect cell proliferation and apoptosis.
CDB-2914, another SPRM, was also shown to increase
apoptosis and suppress cell proliferation in leiomyomas
(Xu et al., 2005). In that study cultured human uterine
leiomyoma cells were subcultured for 120 h and then
stepped down to serum-free conditions for 12, 24, 48, and
96 h in the absence or presence of graded concentrations
of CDB-2914 between 10–6 and 10–9 M. Compared with
untreated control cultures, CDB-2914 decreased the
number of viable cultured leiomyoma cells and the
PCNA-positive rate in those cells and increased the
TUNEL-positive (apoptotic) cells in a dose-dependent
manner. Western blot analysis revealed that treatment

Table 2. CDB-4124 inhibits the incidence, multiplicity, and weight of mammary tumors.
Groups

Dose-mg

Animals-no.

Incidence-%

Multiplicity

1

0

20

85

3.0

Burden-g
2.60

2

3.0

20

60

2.2

0.62*

3

30.0

20

35*

1.1*

0.26*

*, significant (P < 0.05).
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Table 3. Effect of various agents on proliferation in cynomolgous
monkeys.

2.50

Tumors per rat

2.00

Uterus

1.50

Epithelium

1.00

Breast
Stroma

TXT

BrdU-%

BrdU-%

BrdU-%

0.50

Control

10.0 ± 2.5

2.6 ± 0.6

2.4 ± 1.1

0.00
35

Lupron

3.1 ± 0.8*

2.2 ± 1.0

0.3 ± 0.1*

RU 486

12.6 ± 1.8

3.1 ± 1.0

0.9 ± 0.3

CDB-4124

2.1 ± 2.2*

1.1 ± 0.25*

1.9 ± 0.7

42

49

55

59

62 66 71 76
Days post-MNU

80

84 Autopsy

Figure 2. CDB-4124 inhibits the multiplicity of mammary
tumors. The filled squares are animals receiving control pellets.
The filled diamonds are animals receiving pellets containing 3
mg of CDB-4124; the filled triangles are animals receiving 30 mg
of CDB-4124.

with CDB-2914 significantly decreased PCNA and Bcl2 and increased cleaved caspase-3 and cleaved PARP
expression in a dose-dependent manner, suggesting the
involvement of apoptosis in leiomyoma growth inhibition
and disintegration.
The effects of CDB-4124 on cell proliferation and
apoptosis were assessed in cultured human uterine
leiomyoma smooth muscle (LSM) cells and control
myometrial smooth muscle (MSM) cells in matched
uterine cells (Luo et al., 2010). CDB4124 (10−8–10−6 M) or
vehicle were added to the culture medium for 24, 48, or
72 h. CDB-4124 significantly decreased PCNA antigen,
the number of viable LSM cells, and the antiapoptotic
protein Bcl-2. CDB-4124 also increased apoptosis related
biomarkers cleaved polyadenosine 5′-diphosphate-ribose
polymerase and the tumor suppressor Krüppel-like
transcription factor 11 in a dose- and time-dependent
manner in LSM cells. In matched MSM cells, however,
CDB-4124 did not affect cell proliferation or apoptosis,
indicating that this PRM selectively targets leiomyoma but
not normal uterine smooth muscle cells.
Not all cell systems and conditions show these effects
(Roeder et al., 2011). In order to investigate the role of
apoptosis in mediating the effects of PRMs on uterine
leiomyomas, PR+ fibroid cells, known to be capable
of apoptosis, were grown to 80% confluence in serum
containing and treated for 48 h with 0, 10, 100, or 1000
nmol/L CDB-4124. However, no evidence for increased
apoptosis or elevated caspase-3, determined by Western
blotting, was found. The reasons for this lack of effect in
this system were not identified. It was also unexpected
in the face of clinical and in vitro data to the contrary.
It is possible that the cells employed were resistant to
PRMs, although they were PR+. It is also possible that
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* P < 0.05, compared to controls (t-test).

the progesterone activation required growth factor action
rather than classical action through the PR. The lack
of a coactivator specific for growth in these tumors due
to culturing remains possible although an unsatisfying
answer and one difficult to answer. Subtle changes at the
cellular level can have major effects. The phosphorylation
and sumolyation of PR by intracellular mechanisms can
impact PR action (Daniel and Lange, 2009). Fibroids are
understood to be clonal in nature and thus may vary from
one cell line to another. In any case, this lack of effect may
emerge for some patients under treatment for fibroids with
a PRM. We know not all fibroids respond the same way.
This may justify thoroughly characterizing any subject
on a PRM with a heterogeneous response, i.e. if a subject
with multiple fibroids shows a different response for her
individual fibroids.
PRMs may affect not only the growth and progression
of leiomyomas but also suppress clinical symptoms
of endometriosis. However, little is known on the
morphological base of endometrial changes and the
biomarkers mostly affected. Recent studies by a panel
of pathologists have found that women treated with
various PRMs given at different doses for different time
intervals develop cystic glandular formations previously
not known. They also reported apoptotic cells in cystic
formations, suggesting antiprogestins may induce
apoptosis in endothelial cells and thus suppress their
proliferation (Mutter et al., 2008). In a recent study 58
premenopausal women with endometriosis or uterine
leiomyomas were treated for 3 or 6 months with different
doses of CDB-4124. Endometrial biopsies were taken and
were independently examined by 3 pathologists (Ioffe
et al., 2009). They confirmed previous observations for
cystic formations among endometrial glands and reported
lack of endometrial hyperplasia or carcinomas in treated
patients. The condition of months-long PRM treatment
did not provoke a condition similar to unopposed estrogen
but rather to what they characterized as PAEC, PRM-
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associated endometrial changes, characterized by rare
mitoses, atrophic/cystic structures, and apoptotic bodies.
We have compared the effect of RU486, CDB412,
and Lupron (a GnRH agonist often used to treat human
endometriosis) on the endometrium of cynomolgous
monkeys (Macaca fascicularis). This was done to model
endometriotic lesions of women and disclose effects of
PRMs. The peritoneal cavity of each monkey received
minced pieces of the monkey’s own endometrium. Certain
of these fragments attached and established themselves in
the cavity as lesions resembling endometriosis in size and
appearance. Groups of 7 monkeys were treated orally for
36 weeks with CDB-4124 at 3 different doses of RU-486 or
with placebo. Another group received Lupron IM. Animals
were inspected visually after 18 and 36 weeks of treatment
and sacrificed at the end of the study. Monkeys receiving
Lupron, RU486, and CDB-4124 clearly stopped cycling
and had lowered levels of progesterone. Lupron decreased
serum estrogen compared to control and pretreatment
follicular phase levels but serum estrogen levels were not
different in the monkeys receiving CDB-4124 and RU
486. Although showing little change in size, lesions in
monkeys treated with CDB-4124 differed in appearance,
occurring often as clear cysts. Three monkeys in each
group were injected with BrdU within 24 h of sacrifice to
assess tissue proliferation. Full thickness uterine sections
were stained and examined microscopically for evidence
of proliferation in terms of the % cells incorporating BrdU
(Table 3). Lupron and CDB-4124 decreased proliferation
in the epithelial cells of the endometrium and CDB4124 also decreased stromal proliferation. RU-486 did
not decrease proliferation in either cell type. RU-486 and
CDB-4124 increased apoptosis in the epithelial cells of
the endometrium and CDB-4124 also increased apoptosis
in the breast (Table 4). Lupron did not alter apoptosis in
either cell type. No treatment appeared to alter the stroma.
This dichotomy between RU 486 and CDB-4124 in terms
of proliferation may indicate a functional difference
between these 2 antiprogestins.
6. Cellular mode of action: mammary proliferation and
apoptosis
By employing MDA-MB-231 cells that are ER– and PR–,
researchers transfected cells with PR-complementary
DNA (Lin et al., 1999). They found that PR, in the
absence of ER, affected cell morphology and cell
differentiation biomarkers. Progesterone induced
E-cadherin, cytokeratins, vimentin, and STAT 1, 3, 5a,
and 5b expression, all cell differentiation biomarkers. The
more interesting effect was the negative effect on growth.
Follow on studies (Lin et al., 2003) indicated inhibition
of the p42/44 MAPK pathway, an effect unlike previous
work they cited where progestin activated MAPK. This

Table 4. Effect of various agents on apoptosis in cynomolgous
monkeys.
Uterus

Breast

Epithelium

Stroma

TXT

Apo %

Apo %

Apo %

Control

0.2 ± 0.1

0.7 ± 0.2

0.5 ± 0.3

Lupron

0.2 ± 0.1

0.2 ± 0.1

1.4 ± 0.7

RU 486

0.5 ± 0.1*

0.5 ± 0.1

1.2 ± 0.6

CDB-4124

0.5 ± 0.2*

0.5 ± 0.1

2.6 ± 0.9*

* P < 0.05, compared to controls (t-test).

suggested a set of pathways for regulation that included
MAPK-cyclin D1. The authors thought the fact that these
cells were ER– may have been a major contributor to the
effects seen, an effect that implied cross-talk between ER
and PR in a cellular system with converging signals.
The use of xenographs of breast cancer is a way of
looking at human cancer cells in an animal model. Liang
et al. (2007) used BT-474 and T47D cells without Matrigel
as xenographs in nude mice. These cells will regress
soon after inoculation but that regression is held up if
progesterone or medroxy-progesterone acetate is given.
The effects are sensitive to RU 486. Most interesting is the
apparent dependency on VEGF.
When given by subcutaneous injection over a wide
range of concentrations, CDB-4124 suppressed tumor
growth of DMBA-induced mammary tumors in rats, dosedependently as already described (Wiehle et al., 2007).
Progesterone, on the other hand, stimulated DMBAinduced mammary carcinogenesis and tumor growth and
this was associated with increased cell proliferation and
decreased apoptosis, suggesting that PRMs may act as
inhibitors of apoptosis. CDB-4124 significantly decreased
cell proliferation in DMBA-induced mammary tumors, as
evaluated by Ki-67 antibody reactivity (Table 5).
In order better to understand cellular mechanisms
of CDB-4124-induced inhibition of mammary
carcinogenesis, proliferation activity and apoptosis were
examined in mammary tumors from the Sprague Dawley
rats treated with N-methyl-N-nitrosourea (MNU) (Wiehle
et al., 2011). As mentioned above, treatment increased
latency, and, as shown in Table 2, decreased incidence,
multiplicity (Figure 2), and tumor burden. Decreased
size of mammary tumors was a consequence of decreased
cell proliferation and induced apoptosis. Apoptosis was
evaluated by TUNEL assay and cell proliferation by Ki67 antibody that recognized the cells in all phases of the
cell cycle. As shown in Table 6, CDB-4124 significantly
suppressed Ki-67 positive cells in mammary tumors, from
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Table 5. Effects of CDB-4124 on Ki-67 on rat DMBA tumors.
Group

Treatment

% cells positive

1

Control tumors

13.5 ± 7.8

Compared to
controls (t-test)

n
12

3

RU 486 (10 mg/kg)

12.9 ± 7

P = 0.85

10

4

P4 (Progesterone) (10 mg/kg)

25.7 ± 5.8

P = 0.0007

9

6

4124 (10 mg/kg)

5.1 ± 4.2

P = 0.00

7

11

4124 + P4 (10 + 10)

15.5 ± 12.2

P = 0.66

8

ANOVA = 0.0001

[P4 > Control, RU486, 4124 + P4 > 4124].

Table 6. Effects of CDB-4124 on cell proliferation and apoptosis in mammary tumors.
Treatment

Dose mg/kg

Animals no.

Ki-67 LI%

Control

0

19

30.5 ± 7.1

Proellex

3.0

20

25.4 ± 14.4

Proellex

30.0

20

10.3 ± 4.5

P

Apoptosis LI-%

P__

0.7 ± 0.4
0.001

1.4+0.8

0.05

1.6 ± 0.8

0.01

The differences in the values are significant (P < 0.05) as compared to those of the control animals
(Student-Fisher t-test).

30.5 ± 5.4% in the placebo group to 25.4 ± 14.4% in the
low-dose and further to 10.3 ± 4.5% in the high-dose
group of treated animals. Both doses of CDB-4124 induced
apoptosis in mammary tumors, where 0.7 ± 0.4% apoptotic
cells were detected in the control group vs. 1.4 ± 0.8% in
the low-dose and 1.6 ± 0.8%, in the high-dose group. These
data correlated with decreased proportion of PR+ tumor
cells and with decreased serum progesterone. CDB-4124
did not affect serum estradiol. We examined PR expression
in mammary tumors by immunohistochemistry. CDB4124 decreased the proportion of PR+ cells from 48 ± 11%
in placebo treated to 32 ± 12% in CDB-4124 (30 mg/kg)
treated animals. Although trending lower, CDB-4124 did
not significantly affect the proportion of ER+ cells in the
samples.
Other work has shown the link between PRMs and
apoptosis. CDB-4124 suppressed the growth of ER- and
PR-expressing T47D cells and induced apoptosis (Wiehle
et al., 2011). Cells were treated with 0, 0.1, 1.0, and 10.0 µM
CDB-4124 for 3 days or 6 days, and cell number in triplicate
was determined by cell counter. In addition, caspase 3 as a
biomarker of apoptotic cell death was determined in cells
grown on cover slips. CDB-4124 at 1.0 µM and 10.0 µM
suppressed cell growth in a dose-dependent manner and
the high dose induced cell death in both 3- and 6-days
treated cells.
Women with leiomyoma treated with 50 mg of RU486 every second day for 3 months underwent fine needle
breast biopsies before initiation and after termination of
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treatment (Engman et al., 2008). A significant reduction
in proliferating breast epithelial cells (Ki-67 positive) was
observed in RU-486 treated vs. placebo treated patients,
suggesting that antiprogestin treatment can prevent the
development and progression of ER+ and PR+ breast
cancer by inhibiting mammary epithelial cell proliferation.
Apoptosis was not examined in these patients.
7. Humoral mode of action: serum steroids
One of the observations we made purposefully was the
effect of CDB-4124 on serum steroid levels. A frequent
finding was the presence of estrogen but a loss of
progesterone along with cycling in animals and menstrual
cycling in women. In an unpublished safety study (ZP204), we determined that normal young women who were
being assessed for evidence of liver toxicity provided little
evidence for LH surges or serum progesterone over 10
weeks of treatment dependent on dose. There was some
evidence of cycling at the lowest oral daily dose, 1 mg/
day, but none at daily at doses of 3 mg, 6 mg, 9 mg, or 12
mg. Serum progesterone in women at visit 12, i.e. in the
last week of active dosing, as compared to the follow up
(FU) month when they were no longer taking the drug,
demonstrated a major difference (Figure 3). Even though
these women could no longer be considered cycling by
vaginal bleeding or LH surges, it could be argued that we
“missed” the luteal phases at visit 12. This seems unlikely to
be true for all groups and all individuals in the face of the
FU subjects who demonstrated serum progesterone levels
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Effect of Proellex on Serum
Progesterone

8
Serum progesterone ng/mL

7
6
5
4
V12

3
2

FU

1
0

0

3
6
9
mg of daily Proellex for 10 weeks

12

Figure 3. Serum progesterone in women in the last week of
active dosing, as compared to the follow up (FU) month when
they were no longer taking the drug.

typical of the luteal phase and with a mean progesterone
level in excess of 3 ng/mL. Other studies showed similar
effects at higher doses.
While we were not surprised at the effects at the higher
doses, the efficacy at the lower doses was unexpected. This
suggested a sensitivity of CDB-4124 towards provoking
meaningful changes in the gonadotropin hormones that
are responsible for cycling and for hormones, especially
progesterone from the corpus lutea. This had been seen in
early studies of RU 486 (Ortmann et al., 1994). The effects
on cycling suggest a central effect on the hypothalamus/
pituitary with major effects that result in acyclicity. The
hypothalamus receives multiple inputs and the KNDy
neurons of that tissue possess both ER and PR receptors,
allowing them to respond to both up- and down-regulatory
signals and control LH release by the pituitary by way of
kisspeptins and/or GnRH (Skorupskaite et al., 2014).
We believe that the effects on serum progesterone
constitute an additional source of effects on sensitive
tissues. This drug-induced hormonal suppression broadly
affects progesterone action. PRMs should be more effective
when the level of ovarian progesterone is low. Thus, a PRM
like CBD-4124 attenuates its own effects by reducing the
competition from endogenous progesterone.
8. Conclusions
We would propose a second line adjuvant therapy for
patients with hormone-dependent breast cancer for
women who fail estrogen-based therapies. That could be
composed of the use of a progesterone antagonist such as
CDB-4124. This is supported by the DBMA results in rats
and by the studies demonstrating effects on proliferation
and apoptosis in many systems. CDB-54124 when used
alone or in combination with other growth factor or cell-

signal-modifying agents could break out of the current
dilemma where estrogen therapies fail because tumors
have circumvented antiestrogen or estrogen depletion
treatments. First line therapy for women with ER–/PR+
tumors should be considered as well, even though the
number of women with such tumors is small. Windowof-opportunity trials such as currently underway at
Northwestern under Seema Khan (NU 12B09, Pre-surgical
Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women
with Stage I-III Primary Breast Cancer) can highlight
possible efficacies while mitigating risk. Neoadjuvant use
may find a place if strong antiproliferative effects can be
documented.
We would propose a chronic prevention paradigm.
The lesson taught here is from both the DMBA and the
MNU studies in rats where potential tumors seem to be
less likely to be detected by difference between groups. The
effects seen on the mammary gland itself, on hormones,
and proliferation/apoptosis are provocative and may
be predictive. Taken together, these data indicate that
CDB-4124, among others, can suppress the development
of precancerous lesions and ER+ mammary tumors
in rats, and may have implications for prevention and
treatment of human breast cancer. Women treated with
PRMs for benign gynecologic indications (fibroids and
endometriosis) for relatively long periods are a set of
individuals who may be monitored.
We would propose the inhibitory effect of CDB-4124
on mammary carcinogenesis to be a consequence, in part,
of decreased progesterone action in the mammary gland.
Perhaps this was shown already by the changes in ductallateral branching or stem cells, which is promoted by
physiological levels of serum progestins. During pregnancy
the high blood levels of progesterone stimulate ductallateral branching, leading to lobular development and milk
production. This has been supported by recent data on
BRCA1/p53-transgenic mice that have shown that RU-486
suppressed mammary carcinogenesis by inhibiting ductallateral branching and lobular differentiation of mammary
epithelial cells (Poole et al., 2006). These data also suggest
that patients with mutations in BRCA1 may benefit from
antiprogestin therapy in breast cancer prevention and
treatment studies. In a different study, PRKO mice have
also shown distinctive mammary gland architecture
with the presence of ducts, but lack of alveoli and lobules
(Bakker et al., 1989). With the cessation of breast feeding
and drop in the progesterone circulation level, apoptosis
plays a critical role in disintegration of these structures.
Castration of mice and rats similarly induces apoptosis
and reduction of mammary lobular structures.
9. New Directions
Future studies should also address the role of CDB-4124
alone, or in combination with tamoxifen or other SERMs,
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with agents like fulvastrant, and aromatase inhibitors
on the modulation of ER and PR signaling. The potential
involvement of specific coactivators and corepressors will
need to be pursued (Katzenellenbogen et al., 1996) as well as
the challenging proposals that PR can work at the same sites
as ER or cross-talk with the ER or other nuclear receptors
(Daniel et al., 2014; Lin et al., 2003; Vicent et al., 2006). The
involvement of peptide growth factors such as EGF and
IGF-1 needs to be addressed (Dressing and Lange, 2009).
Interaction with the membrane PRs (Charles et al., 2010) that
provoke early responses is entirely open to investigation. The
development of resistance in ER+ breast carcinomas after
treatment with tamoxifen may offer additional possibilities
for clinical applications of progesterone receptor antagonists,
alone or cooperatively with other SERMs. We know that
CDB-4124 is compatible with the use of aromatase inhibitors
from in vitro studies (Gupta et al., 2013). Any potential that
progestins play a role in BRCA-1/-2 cancer is a high priority
given the few choices faced by those women and the results
that suggest the involvement of progesterone in that process.
The main challenges for clinical applications of PR
modulators are their potential toxicity and their potential
effects on the modulation of corticosteroids. The topical
use of PRMs for breast cancer, an approach much like the
vaginal suppository use for gynecologic disorders currently
underway in clinical trials at Repros Therapeutics, is one
way to avoid the first pass through the liver and metabolism
and liver toxicity.
Development of novel PR modulators with high receptor
binding affinity and low incidences of toxic effects is highly
desirable for further study in the prevention and treatment
of breast cancer. For completely new chemical entities to
be brought out, agents should be evaluated with tools that
will allow us to recognize their activity in breast tissues and
breast cancer. The determination of their binding in cellfree extracts of PR+ tissues has always been a first step, as
has the use of reporter assays that show potential activation
of a convenient gene through a proximal promoter that is
responsive to progestins. The classical way to differentiate
new PRMs has been to test their antiprogestational activity in
rabbit uterus. Given the nature of tissue-specificity inherent
in PRMs, a method that demonstrates direct effects on breast
tissue would be preferred. The xenographic model of Liang et
al. would be favorable (Liang et al., 2007). The strong effects
seen in virgin mammary glands of mice and rats suggest that
the PRM could be disclosed in that living system as well.
Clearly, the tissue specificity of PRMs and the discovery of
specific progesterone-proliferative modulatory genes and
their suppression by PRMs would be a considerable advance.
This adds not only to the rationalization of progesterone’s
effects in the breast and breast tumors but also the increases
the possibilities that markers of progestin and PRM action
can be discerned.
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One issue that is specific to the use of PRMs and
presents a new situation is the realization that women taking
a drug like CDB-4124 achieve a long-term state of low
progesterone, a progestopenia. Given that that a PRM usually
has antagonist activity, perhaps the term aprogestogenic state
is more appropriate. This is going to be the case for young
women regardless of whether they are under treatment for
benign gynecology or cancer. As pointed out, this lowering
of progesterone contributes to drug efficiency but may have
downsides. Pre- and postmenopausal females have neither
high estrogen nor progesterone levels. The absolute level
that characterizes partial from total lack of progesterone
will be established fully as we utilize the more sensitive LCmass spectroscopy for hormone analysis. As this becomes
widespread, we will be able to delineate levels that are
meaningfully low and sort out the low levels from the very
low levels with reference to physiologic effects. At the same
time, women on PRMs should retain tonic levels of estrogen
in the absence of progesterone. While this might suggest the
establishment of a state of unopposed estrogen, the direct
effect of PRMs on the endometrium producing PAEC (Ioffe
et al., 2009) avoids unopposed estrogenic stimulation.
The downsides to low estrogen for young women are
considerable in terms of well-being and include vaginal
dryness, hot flashes, and bone loss. The downsides to low
progesterone are somewhat harder to identify. These women
are amenorrheic but the condition is not unprecedented.
Certain kinds of popular oral contraceptives allow ovulation
and menstruation 3 to 4 times a year, a situation not unlike
the use of CDB-4124 with off-drug holidays. Anovulation is
the downside; these women are likely to be contracepted but
without the estrogen that is in the usual oral formulation. This
may not a problem for women who smoke and are in danger
of clotting disorders: these individuals would welcome a new
contraceptive that does not contain an estrogen. In a world
where women seek oral contraception, another form is not
a drawback unless lowering progesterone itself and blocking
residual progesterone activities have negative effects. This
should be an area of investigation to be followed.
In the last 10 years, it has become recognized that
progesterones play a role in mammary proliferation and
breast cancer presents a new challenge. Taken on the
broadest possible terms, monthly cyclic progesterone and, in
the modern world, exogenous progestins seem to pose a risk
for breast cancer. Is breast cancer in older women the price
women pay for being fertile when they were young? If that
were the trade-off, widespread fertility trumps the marginal
risk of dread disease after the child-bearing years, taking the
long view of history with a nod to evolution. Certainly, given
that Homo sapiens spent most of its history in small isolated
groups where child-bearing and nurturing were existential,
the deadly bargain makes a kind of perverse sense. However,
it is not a good bargain for women in our times and perhaps
there is an opportunity to cheat that fate, if that is indeed
what we face.
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